Lam, M, Chia-Yen, C, Yan, X
, Hill, WD, Trampush, JW, Yu, J, Knowles, E
, Davies, G, Stahl, E, Huckins, L, Liewald, DC, Djurovic, S, Melle, I, Christoforou, A, Reinvang, I, DeRosse, P, Lundervold, AJ, Steen, VM, Espeseth, T, Räikkönen, K, Widen, E, Palotie, A, Eriksson, JG, Giegling, I, Konte, B, Hartmann, AM, Roussos, P, Giakoumaki, S, Burdick, KE, Payton, A, Ollier, W, Chiba-Falek, O, Koltai, DK, Need, AC, Cirulli, ET, Voineskos, AN, Stefanis, NC, Avramopoulos, D, Hatzimanolis, A, Smyrnis, N, Bilder, RM, Freimer, NA, Cannon, TD, London, E, Poldrack, RA, Sabb, FW, Congdon, E, Conley, ED, Scult, MA, Dickinson, D, Straub, RE, Donohoe, G, Morris, D, Corvin, A, Gill, M, Hariri, AR, Weinberger, DR, Pendleton, N, Bitsios, P, Rujescu, D, Lahti, J, Hellard, SL, Keller, MC, Andreassen, OA
, Deary, IJ, Glahn, DC, Chunyu, L, Malhotra, AK & Lencz, T 2021, '
Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics',
Neuropsychopharmacology.
https://doi.org/10.1038/s41386-021-01023-4